Septerna’s Post

Proud to see our very own Matt Williams and Guy Checketts featured in The Guardian in a series of articles exploring digital therapeutics and the challenges of bringing them to market. We’re sharing key insights on navigating NHS adoption and other critical hurdles in the journey to success. Read the full articles for expert advice! https://lnkd.in/eeCxgzTd #DigitalHealth #HealthcareInnovation #DTx #TheGuardian

Looking forward to our panel “The Rise of Digital Therapeutics in Clinical Care” today MedTech World with Gina Itzikowitz Florian K. Daniel Young Laura Parker Sharing an article related to our discussion today: “Digital therapeutics from bench to bedside” #medtech24

In this K-Cast episode, Diana Brixner, discusses the level of clinical evidence payers should expect and require from non-prescription digital health tools compared to FDA-approved digital therapeutics! Brixner offers insight as to where the biggest gaps in evidence generation for digital therapeutics come from. Watch here: https://bit.ly/4drOvLE #ManagedCare #DigitalHealth

Your website is more important than you think 💡 Stopwatch Creative work rebranding Mahajan Therapeutics, later led to an acquisition by BayMark Health Services! Learn more on stopwatchcreative.com

Xentria is proud to announce a major operational milestone with the global expansion of multiple biosimilar clinical trials in our growing portfolio. This achievement highlights our commitment to collaboration and advancing therapeutics towards improved healthcare outcomes.      To learn more: https://lnkd.in/gGBGVsfB

Today, I am attending Pathways to Access Summit, a pre-ICPR event. Looking forward to learning about perspectives of implementing psychedelic therapeutics into healthcare in Europe! #PathwaysToAccessSummit #ICPR #PsychedelicTherapeutics

In a recent CRA webinar on evolving business models for DTx (Digital Therapeutics) Rhett Johnson and Andy Parece discussed with a panel of industry leaders, Richard DeNunzio, Omar Manejwala, M.D., and Brion Raymond, how events in the past year, from introduction of new HSPCS billing codes to Pear Therapeutics’ bankruptcy and the transition of some DTx manufacturers to alternative business models, impact their companies. Each panelist discussed business models their company is employing, including prescription digital therapeutics, collaboration with employers to fund solutions and with pharma companies to collaborate partner in research and commercialization. The discussion covered the drivers behind the choice of each business model as well as their advantages, and showed how they are related to the specific product, indication and available clinical evidence base. To learn more and watch the webinar recording, click here: https://lnkd.in/gjdbCBTd #DigitalTherapeutics

Phacilitate #ATW25 in Dallas is next week and I will be chairing the session "Considering the End Early" 🗓️ January 21st at 12.15pm 📍 Theatre 1 Today, I am introducing Scott Jones Ph.D., CSO of BioBridge Global! His presentation "Potency Assay Development - If You’re Not Early, You’re Late!" will take us through the #potency assay development journey. The FDA has been clear over the last few years: POTENCY is a key factor in #productdevelopment. It takes time to develop the potency matrix you need, so thinking of it EARLY will be key! ❓You can add your anticipated questions to our speakers in the comments below or DM me if you prefer. The more questions, the more we'll get out of our incredible speakers! She will be joined by Donna Rill (Triumvira Immunologics, Inc.), David Hermanson (Bio-Techne) and Kasia Averall (Quell Therapeutics). Mark your calendars, you're in for a treat. 🧁 #celltherapy #advancedtherapies #immunotherapy #autoimmune #regulatory Ry Leahy

Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025 Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco, January 13-16. During the event, Vivacelle's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.  KANSAS CITY, Mo., Jan. 9, 2025 /PRNewswire https://lnkd.in/en7HBCge

There are several key reasons why CELT's focus is specifically creating long-acting therapeutics options for patients in need. However, with them comes important additional considerations we must take into account. Learn more about both in our video: (to add captions, click the 'CC' button in the bottom of the video screen) https://lnkd.in/ek26dg_c